Dr Reddy's Labs

Market Cap: Large Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE089A01031
NSEID: DRREDDY
BSEID: 500124
View on NSE | View on BSE

INR

1,252.55

-46.4 (-3.57%)

BSENSE

Mar 23

BSE+NSE Vol: 21.71 lacs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,252.55",
    "chg": -46.4,
    "chgp": "-3.57%",
    "dir": -1,
    "prev_price": "1,298.95",
    "mcapval": "106,268.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Mar 23",
    "curr_time": "",
    "bse_nse_vol": "21.71 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 23, 2026",
    "traded_date_str": "2026 03 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure on 23 Mar 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-low-amid-price-pressure-on-23-mar-2026-3908207",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_priceRelatedfactors_3908207.png",
        "date": "2026-03-23 15:01:03",
        "description": "Dr Reddys Laboratories Ltd experienced a notable intraday decline on 23 Mar 2026, touching a low of Rs 1260.05, reflecting a 2.99% drop from previous levels amid broader market weakness and sectoral pressures."
      },
      {
        "title": "P/E at 19.41 vs Industry's 31.90: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3906712",
        "imagepath": "",
        "date": "2026-03-23 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Industry Premiums</strong></p>\n                <p>The P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 19.41 stands well below the industry average of 31.90, signalling a valuation discount of approximately 39%. This gap suggests that the market is pricing in either a more cautious outlook on the company's earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> remains valued more conservatively. <..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3902447",
        "imagepath": "",
        "date": "2026-03-20 09:20:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity market landscape. This membership not only reflects the company’s substantial market capitalisation—currently standing at ₹1,08,350.52 crores, categorising it firmly as a large-cap stock—but also ensures heightened visibility among domestic and international investors. Index inclusion typically results in increased liquidity and trading volumes, as many passive funds and ETFs track the Nifty 50, mandating investment in its components.</p>\n                <p>Dr Reddys’ presence in this benchmark index also signals its role as a bellwether for the Pharmaceuticals & Biotechnology sector, which is a criti..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-3899623",
        "imagepath": "",
        "date": "2026-03-19 09:21:02",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity landscape. The index, representing the top 50 companies by free-float market capitalisation, serves as a benchmark for institutional investors and mutual funds. Inclusion ensures enhanced liquidity, greater visibility, and often, a more stable investor base. For Dr Reddys, this status affirms its market leadership within the Pharmaceuticals & Biotechnology sector, which is critical given the sector’s evolving dynamics and competitive pressures.</p>\n                <p>With a market capitalisation of ₹1,05,867.42 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its weight in the index. ..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3898159",
        "imagepath": "",
        "date": "2026-03-18 09:21:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being a constituent of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a benchmark for institutional investors and passive funds alike. Inclusion ensures that Dr Reddys benefits from consistent inflows from index-tracking funds, which can provide a stabilising effect on its share price during volatile market phases.</p>\n                <p>With a market capitalisation of ₹1,06,965 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its eligibility for index membership. This status also e..."
      },
      {
        "title": "Dr Reddys Laboratories Upgraded to Hold on Technical and Valuation Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-upgraded-to-hold-on-technical-and-valuation-improvements-3895924",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/DrReddysLaborat_mojoScore_3895924.png",
        "date": "2026-03-17 08:31:44",
        "description": "Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 16 March 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and quality parameters. Despite recent quarterly setbacks, the company’s long-term fundamentals and evolving market signals have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Faces Downgrade Amid Mixed Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amid-mixed-market-performance-3892925",
        "imagepath": "",
        "date": "2026-03-16 09:20:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among institutional investors and inclusion in numerous index-tracking funds. This status often translates into increased liquidity and a stable investor base, which can cushion the stock against market volatility. The company’s large-cap stature and sector leadership in Pharmaceuticals & Biotechnology further reinforce its benchmark relevance.</p>\n                <p>However, membership also brings heightened scrutiny and performance expectations. Dr Reddys’ current mojo grade downgrade from Hold to Sell on 09 Mar 2026, with a mojo score of 48.0, signals a cautious stance from analysts,..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd’s Mixed Week: -0.84% Price Change Amid Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltds-mixed-week--084-price-change-amid-technical-shifts-3891122",
        "imagepath": "",
        "date": "2026-03-14 13:06:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>09 Mar:</strong> Stock opens at Rs.1,286.40 amid broad market weakness</p>\n                    <p><strong>10 Mar:</strong> Intraday high surge of 3.23% to Rs.1,326.50; Mojo Grade downgraded to Sell</p>\n                    <p><strong>11 Mar:</strong> Price rebounds with 2.28% gain to Rs.1,325.50; technical momentum shifts sideways</p>\n                    <p><strong>12-13 Mar:</strong> Price retreats, closing week at Rs.1,293.00 (-0.51% and -1.95% respectively)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,286.40</div></div>\n                    <div cl..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-market-signals-3888249",
        "imagepath": "",
        "date": "2026-03-13 09:20:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index confers considerable visibility and liquidity advantages to Dr Reddys Laboratories Ltd. The index membership ensures that the stock is a focal point for institutional investors, index funds, and exchange-traded funds (ETFs), which track the benchmark. This status often results in enhanced trading volumes and tighter bid-ask spreads, facilitating smoother price discovery. Moreover, inclusion in the Nifty 50 mandates adherence to stringent corporate governance and financial performance standards, which investors closely monitor.</p>\n                <p>Dr Reddys Laboratories Ltd’s market capitalisation stands robust at ₹1,09,960.04 crores, categorising it firmly as a large-cap ent..."
      }
    ],
    "total": 503,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "21-Mar-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "17-Mar-2026",
      "details": "Disclosure under regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "13-Mar-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories Ltd Hits Intraday Low Amid Price Pressure on 23 Mar 2026

2026-03-23 15:01:03

Dr Reddys Laboratories Ltd experienced a notable intraday decline on 23 Mar 2026, touching a low of Rs 1260.05, reflecting a 2.99% drop from previous levels amid broader market weakness and sectoral pressures.

Read full news article

P/E at 19.41 vs Industry's 31.90: What the Data Shows for Dr Reddys Laboratories Ltd

2026-03-23 09:20:50

Valuation Picture: Discount Amidst Industry Premiums

The P/E ratio of Dr Reddys Laboratories Ltd at 19.41 stands well below the industry average of 31.90, signalling a valuation discount of approximately 39%. This gap suggests that the market is pricing in either a more cautious outlook on the company's earnings growth or perceives higher risks relative to its peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to growth prospects and innovation pipelines, yet Dr Reddys Laboratories Ltd remains valued more conservatively. <...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics

2026-03-20 09:20:55

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity market landscape. This membership not only reflects the company’s substantial market capitalisation—currently standing at ₹1,08,350.52 crores, categorising it firmly as a large-cap stock—but also ensures heightened visibility among domestic and international investors. Index inclusion typically results in increased liquidity and trading volumes, as many passive funds and ETFs track the Nifty 50, mandating investment in its components.

Dr Reddys’ presence in this benchmark index also signals its role as a bellwether for the Pharmaceuticals & Biotechnology sector, which is a criti...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Market Signals

2026-03-19 09:21:02

Significance of Nifty 50 Membership

Being part of the Nifty 50 index places Dr Reddys Laboratories Ltd at the forefront of India’s equity landscape. The index, representing the top 50 companies by free-float market capitalisation, serves as a benchmark for institutional investors and mutual funds. Inclusion ensures enhanced liquidity, greater visibility, and often, a more stable investor base. For Dr Reddys, this status affirms its market leadership within the Pharmaceuticals & Biotechnology sector, which is critical given the sector’s evolving dynamics and competitive pressures.

With a market capitalisation of ₹1,05,867.42 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its weight in the index. ...

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership and Institutional Dynamics

2026-03-18 09:21:05

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange, serves as a benchmark for institutional investors and passive funds alike. Inclusion ensures that Dr Reddys benefits from consistent inflows from index-tracking funds, which can provide a stabilising effect on its share price during volatile market phases.

With a market capitalisation of ₹1,06,965 crores, Dr Reddys comfortably qualifies as a large-cap entity, reinforcing its eligibility for index membership. This status also e...

Read full news article

Dr Reddys Laboratories Upgraded to Hold on Technical and Valuation Improvements

2026-03-17 08:31:44

Dr Reddys Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 16 March 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and quality parameters. Despite recent quarterly setbacks, the company’s long-term fundamentals and evolving market signals have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Dr Reddys Laboratories Ltd Faces Downgrade Amid Mixed Market Performance

2026-03-16 09:20:51

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable advantages to Dr Reddys Laboratories Ltd, including enhanced visibility among institutional investors and inclusion in numerous index-tracking funds. This status often translates into increased liquidity and a stable investor base, which can cushion the stock against market volatility. The company’s large-cap stature and sector leadership in Pharmaceuticals & Biotechnology further reinforce its benchmark relevance.

However, membership also brings heightened scrutiny and performance expectations. Dr Reddys’ current mojo grade downgrade from Hold to Sell on 09 Mar 2026, with a mojo score of 48.0, signals a cautious stance from analysts,...

Read full news article

Dr Reddys Laboratories Ltd’s Mixed Week: -0.84% Price Change Amid Technical Shifts

2026-03-14 13:06:11

Key Events This Week

09 Mar: Stock opens at Rs.1,286.40 amid broad market weakness

10 Mar: Intraday high surge of 3.23% to Rs.1,326.50; Mojo Grade downgraded to Sell

11 Mar: Price rebounds with 2.28% gain to Rs.1,325.50; technical momentum shifts sideways

12-13 Mar: Price retreats, closing week at Rs.1,293.00 (-0.51% and -1.95% respectively)

Week Open

Rs.1,286.40

Read full news article

Dr Reddys Laboratories Ltd: Navigating Nifty 50 Membership Amid Mixed Market Signals

2026-03-13 09:20:58

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable visibility and liquidity advantages to Dr Reddys Laboratories Ltd. The index membership ensures that the stock is a focal point for institutional investors, index funds, and exchange-traded funds (ETFs), which track the benchmark. This status often results in enhanced trading volumes and tighter bid-ask spreads, facilitating smoother price discovery. Moreover, inclusion in the Nifty 50 mandates adherence to stringent corporate governance and financial performance standards, which investors closely monitor.

Dr Reddys Laboratories Ltd’s market capitalisation stands robust at ₹1,09,960.04 crores, categorising it firmly as a large-cap ent...

Read full news article

View All News